University of Patras
Ανάδειξη νεφροπροστατευτικής δράσης φαρμακευτικών παραγόντων σε πειραματικό μοντέλο ισχαιμίας επαναιμάτωσης στον επίμυ
Abstract
dc:descriptionAim of the study: Despite the wide progress in the understanding of the pathophysiological mechanisms underlining ischemia reperfusion injury of the kidney, currently there is lack of available pharmacological substances against the phenomenon for use in the clinical setting. In this study we investigate the ability of vardenafil, a widely used phosphodiesterase 5 (PDE5) inhibitor, to attenuate ischemia reperfusion injury in a experimental model in rats. Materials and methods: In total, 71 Wistar rats were divided into 7 groups including a sham group, a control group, 4 vardenafil treated groups, in which 0.02, 0.2, 2 and 20 μg/kg of substance was administered IV one hour before ischemia and a group in which 2 μg/kg of vardenafil was administered IV upon initiation of reperfusion. Animals were subjected to left nephrectomy and right kidney ischemia for 45 minutes via clamping of renal pedicle. After 4 hours of reperfusion animals were either sacrificed and blood and urine sampling as well as their kidneys were retrieved for analysis or they were subjected to renal scintigraphy. Evaluated parameters were serum creatinine, fractional excretion of Na (FENa), renal histology, scintigrphic perfusion, cGMP, ERK and pERK tissue levels. Results: Administration of vardenafil before ischemia resulted in reduction of plasma creatinine and FENa levels, ameliorated histological deterioration in ischemic kidneys and improved scintigraphic renal perfusion. In the highest tested dose of 20 μg/kg biochemical and histological assessment of renal function and morphology of ischemic kidneys did not differ statistically from sham group in which animals did not undergo ischemia. The underlying mechanism of cytoprotection involves elevation of cGMP levels and ERK phosphorylation. Administration of vardenafil after ischemia did not demonstrated any renal protection Conclusions: A wealth of data, part of which are enclosed in current thesis, demonstrate significant renoprotective properties for PDE5 inhibitors against renal ischemia reperfusion injury in the experimental setting. Adding the excellent safety profile of such drugs, their use against renal ischemia reperfusion injury is humans is regarded as very attractive and promising.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kyriazis, Iason
- Κυριαζής, Ιάσων
Subjects
dc:subject × 18Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42113